Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | CFD | P00746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1541274 | 1.00 | MAOA (0.55) | MAOAMAOBHTR2AHRH1BCL2L1 | |
| SCHEMBL9951252 | 1.00 | MAOA (0.55) | MAOAMAOBHTR2AHRH1BCL2L1 | |
| SCHEMBL376197 | 0.89 | MAOA (0.50) | MAOAMAOBHTR2AHRH1BCL2L1 | |
| SCHEMBL1540363 | 0.85 | MAOA (0.54) | MAOAMAOBHTR2AHRH1BCL2L1 | |
| SCHEMBL1539939 | 0.84 | MAOA (0.49) | MAOAMAOBHTR2AHRH1BCL2L1 | |
| SCHEMBL1539982 | 0.83 | MAOA (0.56) | MAOAMAOBHTR2AHRH1BCL2L1 | |
| SCHEMBL1111740 | 0.83 | MAOA (0.56) | MAOAMAOBHTR2AHRH1BCL2L1 | |
| SCHEMBL19145390 | 0.83 | MAOA (0.51) | MAOAMAOBSLC6A4MTNR1AMTNR1B | |
| SCHEMBL1540481 | 0.83 | MAOA (0.51) | MAOAMAOBSLC6A4MTNR1AMTNR1B | |
| SCHEMBL21179229 | 0.83 | MAOA (0.47) | MAOAMAOBMTNR1AMTNR1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-3459945-A1 | BCL-2/BCL-XL INHIBITORS FOR USE IN THE TREATMENT OF CANCER | The Regents of The University of Michigan (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-2668180-B1 | BCL-2/BCL-XL INHIBITORS FOR USE IN THE TREATMENT OF CANCER | UNIV MICHIGAN REGENTS (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3095784-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9493431-B2 | Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| EP-2387559-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-20100022773-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. | 2010-01-28 | — | — | US | disclosed |
| US-7642260-B2 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7585858-B2 | N-sulfonylcarboximidamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-09-08 | — | — | US | disclosed |
| US-7358251-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | MAOA 2958/4885MAOB 2943/4885HTR2A 3715/4885 |
| US-20070015787-A1 | Apoptosis promoters | BAX, BCL2, API5 | MAOA 2958/4885MAOB 2943/4885HTR2A 3715/4885 |
| US-20060258657-A1 | Apoptosis promoters | BAX, BCL2, API5 | MAOA 2958/4885MAOB 2943/4885HTR2A 3715/4885 |
| US-20100022773-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | MAOA 2958/4885MAOB 2943/4885HTR2A 3715/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | MAOA 3900/4885MAOB 3134/4885HTR2A 4096/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | MAOA 1561/4885MAOB 1369/4885HTR2A 1099/4885 |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | BAX, BCL2, BAD | MAOA 3729/4885MAOB 3196/4885HTR2A 2426/4885 |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | BCL2A1, BAX, BCL2L1 | MAOA 4170/4885MAOB 3740/4885HTR2A 4231/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | MAOA 1944/4885MAOB 811/4885HTR2A 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.